IMAC Holdings Completes First Infusion of Stem Cells in Clinical Study for the Treatment of Bradykinesia Due to Parkinson’s...
December 30 2020 - 9:00AM
IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or the “Company”), a
provider of innovative medical advancements and care specializing
in regenerative rehabilitation orthopedic treatments without the
use of surgery or opioids, announces it completed the first
infusion of its investigational compound utilizing umbilical
cord-derived allogenic mesenchymal stem cells in its Phase 1
clinical trial for the treatment of bradykinesia, or the gradual
slowing and loss of spontaneous body movement, due to Parkinson’s
disease.
“The first infusion of our proprietary compound
is a significant milestone in its development, as well as in the
development of IMAC, expanding our capabilities as a regenerative
rehabilitation company,” said Jeffrey Ervin, Chief Executive
Officer of IMAC. “We have already received significant interest
from patients across our regenerative medicine centers to
participate in the trial, and we are actively screening these
inquiries to identify those who fit the inclusion criteria of the
trial. We anticipate full patient enrollment by the end of February
2021, with subsequent infusions continuing in early 2021.”
The first infusion was delivered on December 29,
2020, by trial lead investigator Ricardo Knight, M.D., M.B.A. at
the Company’s Brentwood, Tennessee facility. The Phase 1 clinical
trial, consisting of a 15-patient dose escalation safety and
tolerability study, will be conducted at three of IMAC’s clinical
centers in Chesterfield, Missouri, Paducah, Kentucky, and
Brentwood, Tennessee. The trial will be divided into three groups:
(1) five patients with bradykinesia due to Parkinson’s disease will
receive a low dose, intravenous infusion of stem cells, (2) five
patients will receive a medium intravenous dose, and (3) five
patients will receive a high intravenous dose. All groups will be
tracked for 12 months. IMAC’s medical doctors and physical
therapists at the clinical sites have been trained to administer
the treatment and manage the therapy.
About IMAC Holdings, Inc.
IMAC was created in March 2015 to expand on the
footprint of the original IMAC Regeneration Center, which opened in
Kentucky in August 2000. IMAC Regeneration Centers combine life
science advancements with traditional medical care for movement
restricting diseases and conditions. IMAC owns or manages 15
outpatient clinics that provide regenerative, orthopedic and
minimally invasive procedures and therapies. It has partnered with
several active and former professional athletes, opening six Ozzie
Smith IMAC Regeneration Centers, two David Price IMAC Regeneration
Centers, as well as Mike Ditka IMAC Regeneration Centers and a Tony
Delk IMAC Regeneration Center. IMAC’s outpatient medical clinics
emphasize its focus around treating sports and orthopedic injuries
and movement-restricting diseases without surgery or opioids. More
information about IMAC Holdings, Inc. is available at
www.imacregeneration.com.
Safe Harbor Statement
This press release contains forward-looking
statements. These forward-looking statements, and terms such as
“anticipate,” “expect,” “believe,” “may,” “will,” “should” or other
comparable terms, are based largely on IMAC's expectations and are
subject to a number of risks and uncertainties, certain of which
are beyond IMAC's control. Actual results could differ materially
from these forward-looking statements as a result of, among other
factors, risks and uncertainties associated with its ability to
raise additional funding, its ability to maintain and grow its
business, variability of operating results, its ability to maintain
and enhance its brand, its development and introduction of new
products and services, the successful integration of acquired
companies, technologies and assets, marketing and other business
development initiatives, competition in the industry, general
government regulation, economic conditions, dependence on key
personnel, the ability to attract, hire and retain personnel who
possess the skills and experience necessary to meet customers’
requirements, and its ability to protect its intellectual property.
IMAC encourages you to review other factors that may affect its
future results in its registration statement and in its other
filings with the Securities and Exchange Commission. In light of
these risks and uncertainties, there can be no assurance that the
forward-looking information contained in this press release will in
fact occur.
IMAC Press Contact:
Laura Fristoe
lfristoe@imacrc.com
Investor Relations:
Bret Shapiro
(516) 222-2560
brets@coreir.com
IMAC (NASDAQ:IMAC)
Historical Stock Chart
From Aug 2024 to Sep 2024
IMAC (NASDAQ:IMAC)
Historical Stock Chart
From Sep 2023 to Sep 2024